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In the context of regenerative medicine, based on the potential of stem cells to restore diseased tissues, epigenetics is becoming
a pivotal area of interest. Therapeutic interventions that promote tissue and organ regeneration have as primary objective the
selective control of gene expression in adult stem cells.This requires a deep understanding of the epigeneticmechanisms controlling
transcriptional programs in tissue progenitors. This review attempts to elucidate the principle epigenetic regulations responsible of
stemcells differentiation. In particularwe focus on the current understanding of the epigenetic networks that regulate differentiation
of muscle progenitors by the concerted action of chromatin-modifying enzymes and noncoding RNAs. The novel exciting role
of exosome-bound microRNA in mediating epigenetic information transfer is also discussed. Finally we show an overview of the
epigenetic strategies and therapies that aim to potentiatemuscle regeneration and counteract the progression ofDuchenneMuscular
Dystrophy (DMD).
1. Introduction
Epigenetic regulation of chromatin structure is fundamental
to achieve the activation or repression of transcriptional
programs governing cell development and differentiation.
Changing cell phenotype without affecting genotype, epige-
netics controls the spatial and temporal regulation of gene
expression that ensures the quality, stability, and heritabil-
ity of cell identity. At least three systems, including DNA
methylation, posttranslational histone tail modifications, and
noncoding RNA, are currently involved in epigenetic reg-
ulation [1]. Epigenetic changes occur naturally in normal
development and health but can also be influenced by
several factors including aging and diseases. Indeed aberrant
epigenetic control can cause abnormal activation or silencing
of genes. Importantly epigenetic modifications are reversible
and sensitive to the environment, having therefore the
potential to be therapeuticallymanipulated.Thus, epigenetics
is currently a hot topic for research and the number of
studies relating to various models of epigenetic regulation
is tremendously increasing. Moreover, advances in genome-
wide technologies trying to elucidate epigenetic profiling
(i.e., ChIP-seq, ChIA-PET, and Hi-C) hold the promise to
deeply clarify the epigenetic control of cellular identity in
health and disease.
Adult stem cells are candidate targets of epigenetic
therapies toward repairing injured or diseased tissues, so
they represent a key issue in regenerative medicine. In this
context, skeletal muscle regeneration provides an insightful
model for the study of the epigenetic events supporting the
synchronized activation and repression of gene expression
during stem cells differentiation. Indeed adult muscle stem
cells remain in an embryonic-like state during development
with the long-term ability to self-renewal and differentiate
in response to injury [2]. A global genome reorganization
allows activation, proliferation, and subsequent differenti-
ation of quiescent progenitor muscle cells into functional
multinucleated myofibers. Satellite cells are the main source
of muscle stem cells (MuSCs) that regenerate adult skeletal
muscles during postnatal life [3]. Intriguingly during aging or
muscular disorders in which there is a chronic loss of skeletal
muscle structure, the satellite cells function is compromised
[4] even if their endogenous capacity to regenerate is not
affected [5]. In fact it was demonstrated that the muscle
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environment is critical to permit effective muscle regenera-
tion [6]. In particular the recently identified population of
muscle interstitial cells, named fibroadipogenic progenitors
(FAPs), plays a key role in supporting MuSCs activity and
regeneration. However, in chronic muscle damage these
cells lose their ability to support MuSCs mediated muscle
regeneration and differentiate into fibroblasts and adipocytes
[7–11]. An extensive analysis of the epigenome of these
cells in healthy and diseased muscles is currently missing
and would be crucial to better understand and pharmaco-
logically manipulate changes that affect their regeneration
activity.
The most severe neuromuscular disease is the Duchenne
Muscular Dystrophy (DMD), a rare X-linked genetic dis-
ease caused by mutations in the dystrophin gene. DMD is
characterized by a rapid progression of muscle degeneration
that leads to the loss of ambulation and death within the
second decade of life. In DMD the unbalanced regeneration
of muscles exposed to continuous waves of degeneration
leads to replacement of contractile myofibers with fibrotic
and fatty tissue [12, 13]. Nowadays there is not available
cure for dystrophic patients and treatment is restricted to
strategies that counteract the progression of the disease. The
only therapy is limited to using corticosteroids as drugs to
improve muscle strength. A huge number of studies for the
treatment of the muscular disease are arising and some of
them are undergoing clinical investigation. Gene and cell-
therapies, acting to repair the genetic defect, represent the
most promising curative approach in the treatment of DMD
but are still far from clinical translation [14].
Otherwise, pharmacological approaches that target the
pathological consequences of the genetic defect are easy
prompt to clinical practice translation. Actually, the phar-
macological therapy for DMD includes nitric oxide (NO)
administration, insulin-like growth factor 1 (IGF-1) stimu-
lation, and myostatin inhibition in way to increase skeletal
muscle mass; otherwise, therapies leading the inhibition of
the transforming growth factor-beta (TGF𝛽) pathway, mod-
ulation of nuclear factor-𝜅B (NF-𝜅B), and tumor necrosis
factor-𝛼 (TNF-𝛼) signalling are used to reduce fibrosis and
inflammation in muscle [15].
However, the major limitation of manipulating target
pathways consists in the lack of selectivity resulting in unde-
sired side effects. Thus, regenerative medicine is providing
novel strategies developing several epigenetic drugs aimed
to manipulate the chromatin targets of individual signalling
pathways. In the context of DMD, Histone Deacetylase
Inhibitors (HDACi) are emerging as promising treatment
to increase the functional and morphological recovery of
dystrophic muscles [16–18]. Most of the beneficial effects
of HDACi arise from their ability to activate a microRNA-
SWI/SNF based epigenetic network in FAPs that redirects
their lineage commitment from a fibroadipogenic toward a
myogenic fate [19].
MicroRNAs (miRs) belong to the small noncoding RNAs
family and are known to control numerous biological pro-
cesses representing themost prevalent regulatorymechanism
of mRNA availability in cells [20]. Apart from their role
in regulating cell-autologous epigenetic events, miRs are
involved also in cell-to-cell communication being involved in
epigenetic regulation of recipient cells. miR shuttle between
cells appears to be preserved and mediated by extracel-
lular vesicles (i.e., exosomes) that are emerging as potent
genetic transfer agents [21]. Interestingly stem cell-derived
extracellular vesicles appear to be naturally equipped to
mediate tissue regeneration and recent evidence suggests
their therapeutic potential for targeted delivery of exogenous
miRs [22].
In this review, we will focus on the principal epige-
netic regulatory mechanisms underpinning skeletal muscle
regeneration and their potential manipulation to develop
pharmacological therapies for the treatment of DMD.
2. Chromatin-Modifying Enzymes:
Epigenetic Writers and Erasers Regulating
Cell Epigenome
The temporally regulated gene expression that controls
pluripotency and differentiation is achieved by highly coordi-
nated epigenetic events that ensure lineage commitment and
cell fate determination. Epigenetic regulation of chromatin
structure is fundamental to the activation or repression of
specific transcriptional programs and is mainly controlled by
chromatin-modifying enzymes that induce DNA methyla-
tion, posttranslational histone tail modifications, and nucle-
osome remodelling.
DNA methylation is a heritable, yet reversible, epige-
netic modification that plays a central role in transcrip-
tional repression. DNA methyltransferases (DNMTs) cat-
alyze the transfer of a methyl group from cofactor S-
adenosylmethionine to carbon 5 of the cytosines (5mC) that
typically reside within a CpG dinucleotide. Regions of high
CpG density, known as CpG islands, are typically devoid
of DNA methylation [23]. Conversely, genes regulated by
methylation usually contain low CpG density promoters
and are demethylated and expressed in a cell-type-specific
manner during differentiation [24–26]. This process is well
illustrated during skeletal muscle cell fate commitment and
differentiation. During development, pluripotent cells show
a progressive loss of methylation leading to muscle stem
cells with a unique DNA methylation signature associated
with its specialized functions. Specific-myogenic factors such
as MyoD and Myogenin are activated in a demethylation-
dependent manner driving the activation of the myogenic
program (reviewed in [27]). Simultaneously, myogenesis
is accompanied by DNA methylation of pluripotency and
developmental genes (i.e., Hox genes) [28]. Seminal works
demonstrated that treatment with 5-azacytidine, a potent
inhibitor of DNA methylation, triggers myogenic differen-
tiation in nonmuscle cells, linking for the first time MyoD
tissue-specific demethylation and cell fate commitment [29–
31]. DNA demethylation may also provide a transcriptionally
poised state of muscle fiber genes that would be activated
during differentiation, upon the acquisition of transcription
factors and positive histone marks.
Indeed changes in DNA methylation and histone mod-
ifications strongly cooperate to achieve the global genome
Stem Cells International 3
reorganization of progenitor cells necessary to establishmyo-
genic identity, proliferation, and subsequent differentiation.
Satellite cells represent the main source of stem cells for
adult muscle regeneration. Following muscle injury, they are
readily activated and induced to proliferate and differentiate
in multinucleated myofibers [32, 33]. The myogenic lineage
in satellite cells is determined by the expression of Pax3 and
Pax7 genes, while the expression of basic helix-loop-helix
Myogenic Regulatory Factors (MRFs; MyoD, Myf5, Myo-
genin, and MRF4) in cooperation with myocyte enhancer
factor-2 (MEF2) family proteins confers their ability to
form differentiated myofibers [34]. Satellite cells activation is
reflected in drastic changes at specific chromatin regions via
the action of chromatin-modifying enzymes [35].
There are several classes of posttranslational histone
modifications (i.e., phosphorylation, acetylation, methyla-
tion, and ubiquitylation) that affect chromatin structure and
accessibility [36].
Histone acetylation has generally been linked to tran-
scriptional active chromatin and is dynamically regulated by
the opposing activities of histone acetyltransferases (HATs)
and histone deacetylases (HDACs). A large amount of work
illustrated the fundamental role of HATs and HDACs in
regulating muscle development and differentiation. HATs
catalyse the transfer of acetyl groups to lysine residues of
histones, resulting in the relaxation of chromosomal DNA
permissive for transcription. The histone acetyltransferases
p300/CBP and PCAF activate muscle gene expression by
acetylation of MyoD and modulation of its recruitment at
target loci [37]. Interestingly recent studies have highlighted
the ability of MyoD to preset the chromatin landscape of
myoblasts for the activation of muscle-specific genes. Indeed
genome-wide binding of MyoD has been associated with
HATs recruitment and regional histone acetylation [38],
while MyoD-bound distal enhancers have been linked to
the recruitment of additional transcription factors and the
regional enrichment of H3K4 monomethylation (H3K4me1)
and H3K27 acetylation (H3K27ac), two typical markers of
active enhancers [39].
HDACs function to reverse histone acetylation, causing
chromosomal DNA condensing and preventing the unsched-
uled transcriptional activation of muscle-specific genes in
undifferentiated cells. There are currently 18 known human
HDACs grouped into four classes [40]. Classes I, II, and IV
HDACs are zinc-dependent proteins, while class III HDACs
require NAD+ [41].
Interestingly, class I HDACs (HDAC1 and HDAC2) show
constitutive nuclear localization and preferentially associate
with MyoD [42], while class II HDAC members (HDAC4
and 5) shuttle between the nucleus and the cytoplasm and are
dedicated repressors of MEF2-dependent transcription [43,
44]. Upon differentiation, displacement of HDACs from the
chromatin of target genes correlateswith the hyperacetylation
at muscle loci and activation of muscle gene transcription
(i.e., Myogenin and Myosin heavy chain) [45].
Given the importance of the balance between acetylation
and deacetylation in regulating muscle gene transcription,
HDACi are emerging as promising drugs to manipulate the
regenerative potential of stem cells in diseased muscle [15]
(see below). Despite the general assumption that HDAC
inhibition would indiscriminately cause a global hyperacety-
lation in all organs and tissues, several studies revealed a
surprising selective effect of HDACi on embryonic and adult
stem cells [46] and in particular on genes with bivalence
or with preexisting activator marks [15, 47]. Accordingly
genome-wide Chip-seq analysis in myoblasts showed that
the large majority of HDACi induced genes were involved
in the myogenic differentiation program (i.e., Myosin 7
(MyH7), Enolase 3 (ENO3), and Myomesin 1 (MYOM1))
and showed bivalent (42%) or active (57%) epigenetic marks
[48]. This data indicates that, in myoblasts, HDACi enforce
and anticipate the expression of genes that are normally
induced during differentiation. A bivalent chromatin struc-
ture builds an epigenetic signature that identifies genes poised
for transcription typically enriched in stem cells. Poised
genes show bivalent promoters marked by the presence
of both active and repressive histone methylation marks
[49, 50].
Methylation is linked to both active and inactive chro-
matin regions depending on the specific histone and lysine
residue that is targeted. In particular, tri-methylation of lysine
4 on histone H3 (H3K4me3) is associated with transcrip-
tionally active promoters, while tri-methylation of lysine 27
(H3K27me3) leads to chromatin condensation [51].
Differentiated cells usually resolve bivalent promoters
into an active or repressive state [52, 53] and become resistent
to HDACi treatments. Indeed HDACi have been shown
to potentiate myogenesis and the gene expression profile
selectively in proliferating myoblasts and not in terminally
differentiated myotubes. As differentiation precedes, muscle
specific genes (i.e., Myogenin and MCK) gradually lose
H3K27me3 and gain H3K4me3 [54]. Conversely, progenitor-
specific transcription factors (i.e., Pax7) require H3K27me3-
mediated epigenetic repression for myotube maturation [55].
This process is finely regulated by the activity of two classes
of histone lysine methyltransferases: the Polycomb group
proteins responsible of H3K27me3 for epigenetic silencing
and the Trithorax group (TrxG) which activates gene tran-
scription catalyzing H3K4me3.
Dynamic changes in the epigenetic landscape of mus-
cle progenitors during differentiation are coordinated by
extracellular signals that specifically target the activity and
recruitment of chromatin modifier enzymes. For instance,
the regeneration-activated p38 signalling targets multiple
components of the myogenic transcriptosome that is assem-
bled on the chromatin of muscle genes in response to locally
released regeneration cues. p38𝛼/𝛽 kinases phosphorylate
MEF2D mediating the recruitment of the Trithorax enzy-
matic subunit Ash2L to the chromatin of muscle genes [56].
Concomitantly p38𝛼 kinase promotes the phosphorylation
of EZH2, the enzymatic subunit of the Polycomb Repressive
Complex 2 (PRC2), targeting Pax7 promoter for repression
[55]. Finally p38 signalling promotes the recruitment of the
chromatin remodelling SWI/SNF complex to the regulatory
regions ofMyoD-target muscle genes by the phosphorylation
of BAF60c [57].
SWI/SNF complex comprises two mutually exclusive
enzymatic sub-units (the ATPases Brg1 and Brm) and several
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Figure 1: Epigenetic reprogramming of MuSCs and FAPs during differentiation. MuSCs adopt a chromatin permissive structure on
muscle genes in which MyoD and BAF60c-based SWI/SNF complex promote transcription (on the top). FAPs differentiation into
adipocytes is mediated by BAF60a/b-based SWI/SNF complex (on the bottom). HDACi treatment in dystrophic muscles activates a
myomiR/MyoD/BAF60c network that, switching the BAF60 subunits assembled in the SWI/SNF complex, reprograms FAPs toward the
acquisition of a myogenic phenotype.
Brg1/Brm associated factors (BAFs) [58]. In particular, three
alternative variants of Baf60 sub-unit (BAF60a, BAF60b,
and BAF60c) confer the affinity for tissue-specific tran-
scription factors regulating lineage determination in many
cell types [19, 59–61]. BAF60c is essential to activate both
skeletal and cardiac muscle programs [57, 61], while BAF60a
and BAF60b activate alternative lineages, including lipid
metabolism [62]. During embryo myogenesis, the negative
regulation of BAF60a and BAF60b leads in progenitor cells
the activation of a BAF60c-mediated muscle differentiation
program [63].
Intriguingly our recent study demonstrated that BAF60
selection can drive lineage determination in a population of
fibro-adipogenic progenitors (FAPs) resident in skeletal mus-
cles. Favouring BAF60c incorporation in SWI/SNF complex
at expense of BAF60a/b directs the switch from the fibro-
adipogenic to the myogenic lineage reducing fibrosis and fat
deposition in dystrophic muscles (Figure 1) [19, 64]. These
data suggest that therapeutic approaches aim to selectively
target the combinatorial assembly of the SWI/SNF complex
could be used tomanipulate cell fate determination in several
disorders.
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3. Non-Coding RNAs as Epigenetic Regulators
of Gene Expression
A novel emerging level of gene expression regulation is
mediated by non-coding RNAs (ncRNAs): functional RNA
molecules not translated into proteins, composite of struc-
tural and regulatory RNAs. ncRNAs are divided by their
size into long non-coding RNA (lncRNAs) greater than 200
nucleotides to over 100 kb in length and small non-coding
RNA (sncRNAs) with a non-coding transcript long less than
200 nucleotides [65].
LncRNAs localize both in the nucleus and cytoplasm
and have roles in chromatin remodelling, transcription,
intracellular trafficking and post-translational processes con-
trolling cell identity and lineage commitment [66, 67]. LncR-
NAs located in the nucleus regulate transcription recruit-
ing chromatin-modifying enzymes or interacting with RNA
sequences to influence their splicing. Many nuclear lncRNAs
associate with EzH2/PRC2 and control the formation of
nuclear compartments (i.e., speckles, para-speckles, poly-
comb bodies) [68, 69]. lncRNAs identified in cytoplasm
regulate protein localization, mRNA translation and stability.
Intriguingly it was recently described their role as sponge for
miRNAs: reducing miRNAs levels, they inhibit the miRNA-
mRNA mediated target degradation [66]. lncRNAs strongly
regulate MuSCs differentiation. The muscle-specific linc-
MD1 manages the time of muscle differentiation acting as
a sponge to sequester miR-133 and miR-135 that regulate
the expression of MAML1 and MEF2C, pro-myogenic tran-
scription factors [66]. lncRNAs transcribed from MyoD
enhancer (Enhancer RNAs (eRNAs)) regulate alsoMyoD and
Myogenin expression [70].
sncRNAs family include transfer RNAs (tRNAs) and
ribosomal RNAs (rRNAs), as well as microRNAs (miRNAs),
Piwi-interacting RNAs (piRNAs), small interfering RNAs
(siRNAs), small nuclear RNAs (snRNAs) [65]. Recent studies
suggest the existence of thousands of ncRNAs, many of
them involved in the epigenetic regulation of development,
physiology, tissue regeneration and disease [71, 72].Themost
studied small non-coding RNAs are the miRNAs, molecules
containing about 22 nucleotides, expressed in eukaryotes
and found well conserved in plants and animals. miRNAs
regulate numerous biological processes inhibiting translation
of their target mRNA and also mediating their degrada-
tion through recognition of imperfect complementary sites,
usually located in the 3󸀠-untranslated regions [73, 74]. It
seems that miRNAs regulate the expression of more than
50% of mammalian genes making them the most prevalent
regulatory mechanism of mRNA availability [20, 75, 76].
miRNAs may fine tuning distinct processes targeting
specific epigenetic regulators: DNA methylases, PRC com-
ponents, Histone Deacetylases and chromatin remodelling
complexes members [77]. Given their consistent epigenetic
role, miRNAs are important regulators of embryonic and
adult myogenesis [78] controlling MuSCs quiescence, pro-
liferation and differentiation [79, 80]. For instance, Rando’s
group identified in a microarray expression study, about
twenty quiescence-specific miRNAs that actively maintain
the quiescent state of satellite cells (i.e., miR-489 that targets
the oncogene Dek) and 351 miRNAs regulating satellite cells
activation [81].
One crucial step forMuSCs activation ismiR-31 downreg-
ulation that allows Myf5 translation in myoblasts [82]. Myf5,
together with MyoD, leads the activation of miR-133a/b that
inhibit the adipogenic regulator PRDM16 preventing muscle
progenitors cells commitment to adipose cell fate [83, 84].
miR-133 controls also myoblasts proliferation acting as SRF
regulator [85] During myogenesis, miR-1, miR-29 and miR-
206 target HDAC4 promoting the activity of the myogenic
transcriptional elements Mef-2 and MRFs [86]. MRFs in
turn regulate the expression of miR-1, miR-133a/b and miR-
206, muscle specific miRNA defined as “myomiRs”. Finally
miR-1 and miR-206 control Pax3/7 repression [87] while
miR-26a targets the Ezh2 methyltransferase, to allow muscle
differentiation [54, 88].
Different studies demonstrated that miRNAs could mod-
ulate the composition of SWI/SNF chromatin remodelling
complexes in away to epigenetically reprogramcell fate deter-
mination. Crabtree showed a microRNAmediated switching
of chromatin-remodelling complexes in neural development:
miR-9 and miR-124 target BAF53a sub-unit driving differen-
tiation of progenitor cells into neurons [89]. Similarly our
group identified in muscle interstitial FAPs an analogous
miR-based mechanism that regulates the balance toward
myogenic versus alternative fates (fibro-adipogenesis). In
FAPs myomiRs (miR-1,2as, miR-133a and miR-206) favour
the composition of the pro-myogenic BAF60c-SWI/SNF
complex by targeting the alternative BAF60a and BAF60b
variants [19]. Similarly in Embryonic muscle progenitors
myomiRs negatively regulate BAF60a/b to promote the
BAF60c-SWI/SNF complex [63].
Interestingly miRNAs derived from various tissues and
organs, being stable and resistant to nuclease digestion,
are easily detectable in both plasma and serum and may
serve as diseases biomarker. Indeed circulating miRNAs
profile dynamically change in many diseases such as cancer,
myocardial infarction, heart failure, myotonic Distrophy type
I and DMD [90–95]. MyomiRs for instance, have been
identified in serumofmuscular dystrophy animalmodels and
patients where they are passively released as a consequence of
myofibers degeneration and breakdown.Their putative active
role is still unkown and currently they are proposed as novel
diagnostic markers of disease progression. Indeed myomiRs
detection in serum is inversely correlated to muscle health,
representing a more sensible biomarker than the commonly
used Creatine Kinase (CK) [94, 96].
4. Extracellular Vesicles for
Genetic Information Transfer and
Cell Phenotype Modulation
Extracellular vesicles are emerging as potent sources of
genetic information transfer between cells and are involved in
regulating stem cell plasticity via epigenetic reprogramming
and their ability to alter gene regulatory networks [21]. Cell-
derived vesicles such as exosomes and microvesicles possess
the capability to mediate intercellular communication by
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fusing with the plasma membrane of recipient cells and sub-
sequently delivering their cargo, consisting of functional pro-
teins, mRNAs andmiRNAs able to modulate gene expression
and cell phenotype [97]. Exosomes are homogenous small
particles, usually 30 to 100 nm in size, of endosomal origin.
Microvesicles, instead, constitute a larger and heterogeneous
population of extracellular vesicles, 50 to 1000 nm in size,
and are directly produced through the plasma membrane
budding [22].
Multiple cell types have been described to release vesi-
cles in extracellular medium, including mesenchymal cells,
adipocytes, fibroblasts, immune cells and myoblasts. Little is
known about vescicles regulation of MuSCs in health and
diseased muscles. However several studies reporting muscle-
exosomes are emerging [98–100]. Myoblasts and myotubes
use exosome clustered miRNAs as “endocrine signals” to
control important signaling pathways (i.e., Wnt signaling
pathway) for muscle homeostasis and regeneration. MiRNAs
secreted in exosome by myotubes are functionally able
to silence the HDAC Sirt1 in myoblasts, controlling their
commitment to differentiation [88]. Muscle behaviour is
also influenced by vesicles released from different sources,
like mesenchymal stem cells. Indeed it has been recently
shown that miRNAs (i.e., miR-494 and myomiRs) released
in exosomes from mesenchymal stem cells promote muscle
regeneration following injury by enhancing myogenesis and
angiogenesis [101]. Indeed exosomes appear to be naturally
equipped to mediate tissue regeneration and their cargo
constitute a rapid response, protected by the oxidative
environment, to initiate tissue repair [102]. Vesicles from
mesenchymal stem cells were found to confer therapeutic
benefit in a range of different diseases: kidney [103–105] and
hepatic injuries [106] myocardial ischaemia and infarction
[107–109] and peripheral arterial disease [110]; this “regen-
erative” effect is mainly due to the ability of extracellular-
vesicles to induce phenotypic changes in local stem cells
through epigenetic reprogramming to stimulate tissue repair
and regeneration [111]. Notably, the transfer of tissue-specific
mRNAs, miRNAs and protein-based transcription factors
through the extracellular microvesicles was shown to induce
phenotype change in bone marrow cells when co-cultured
with cells derived from various tissues (brain, heart, liver and
lung) [112–114].
Extracellular vesicles mediate communication even
between distally located cells and tissue and can be found
in many biological fluids including blood, saliva, urine,
and breast milk [22]. For instance tumor cells can induce
apoptosis in distal skeletal muscles via exosome assembled
miR-21, which signals through the Toll-like 7 receptor
(TLR7) on myoblasts to promote cell death and cancer
cachexia [115].
Given their ability to be readily isolated from most
body fluids, circulating miRNAs packed into exosomes are
emerging as useful biomarkers to determine the development
and progression of various diseases. Moreover, their natural
role in transferring genetic material both locally and sys-
temically has inspired pharmacological strategies to exploit
these vesicles as therapeutic agents via the introduction of
exogenous genetic cargoes such as siRNA (see below).
5. Epigenetic Therapies and
Future Perspectives for Muscle
Regeneration in DMD
In last years, regenerative medicine focused on the study of
plasticity of stem cells epigenome and the recent findings
lead the researchers to concentrate on strategies aimed to
reprogram the stem cell fate in numerous diseases.
Myogenesis is coordinated by a complex interplay
between epigenetic events that are crucial to control lineage
determination and differentiation of adult stem cells. Basic
research and recent studies of next generation sequencing
are clarifying the fine epigenetic regulation of myogenesis
and which are the epigenetic players that create changes in
the epigenome opening new therapeutic options in muscle
diseases as DMD.
HDACi are considered as the first generation of epige-
netic drugs with proven clinical efficacy in the treatment
of some lymphoid malignancies [116] and are now in clin-
ical trials for a number of other diseases including DMD.
Indeed preclinical studies in dystrophic mice (mdx) showed
their ability to alleviate both morphological and functional
consequences of the primary genetic defect [16, 17]. The
current availability of HDACi in clinical practice gave the
opportunity for an immediate translation of these drugs into
pharmacological treatments of DMD in human patients. The
HDACi ITF2357 (Givinostat) represents the first epigenetic
drug included into a study therapy for DMD.
Givinostat has already been tested in pediatric popula-
tions and received an Orphan Drug Designation by EMA for
the treatment of systemic-onset juvenile idiopathic arthritis
(SOJIA) [117, 118]. This knowledge encouraged its traslation
into a phase I/II clinical trial with children affected by DMD
(ClinicalTrials.gov identifier: NCT01761292). After one year
of treatment Givinostat efficacy has been monitored showing
very promising results on muscle histology and functionality
without severe adverse effects on children health; thus the
trial has been prolonged for a second year. Obviously this
study requires defining the activity of Givinostat in long-term
treatments to assess its persistent effect in dystrophic muscles
and to monitor possible adverse events.
The functional characterization of the recently identified
epigenetic network that determines the ability of HDACi to
promote regeneration of dystrophic muscles, at expense of
fibrosis and fat deposition, highlights the role of FAPs as key
cellular mediators of HDACi activity and DMD progression
[18, 19].
FAPs are multipotent mesenchymal cells located in mus-
cle interstitium with the ability to proliferate and support
satellite cells mediated muscle regeneration in response to
local injury or disease. However, beyond their beneficial role,
FAPs have been shown to be the major source of fibro-
adipocytes in degenerating muscles [9, 10].
Importantly we have demonstrated that treatment with
HDACi at early stages of DMD induces in FAPs a myo-
genic fate at expense of their fibro-adipogenic lineage.
HDACi de-repress a latent myogenic program by activat-
ing a MyoD/BAF60c/myomiR network that leads muscle
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Figure 2: Exosomes as putative mediators of the functional interaction between FAPs and MuSCs. In this model, exosomes released by
activated FAPs support myoblasts differentiation through a mechanism by which their cargo of miRNA can be transferred to MuSCs.
differentiation. Indeed HDACi induce MyoD and BAF60c
expression, two core components of the myogenic transcrip-
tional machinery, and up-regulate myomiRs (miR-1.2, -133
and -206), which target the alternative BAF60 variants A
and B. Switching of the BAF60 sub-units assembled in the
SWI/SNF complex reprograms FAPs toward the acquisition
of a pro-myogenic phenotype. However the progressive
impairment of the integrity of this network prevents HDACi
efficacy at late stages of DMD. Indeed, with the progress of
the disease FAPs becomes resistant to HDACi and acquire
a constitutive fibro-adipogenic lineage replacing the muscle
loss with fatty and fibrotic tissues [18]. Importantly, trans-
plantation of “young” FAPs into muscles of “old” dystrophic
mice, restored the ability of HDACi to promote regeneration
at advanced stages of disease [18]. This suggests that a
powerful future therapeutic strategy will be to epigenetically
reprogram aged FAPs with selective delivery of Baf60c and
myomRs. In this context the natural ability of exosomes to
transfer material both locally and systemically encourage
the possibility of exploiting these vesicles for therapeutic
purposes.
While these data provide new insight into the molecular
pathogenesis of DMD and therapeutic approaches to delay
the disease, they also highlight the potential ofmiRs detection
as clinical biomarkers of disease progression. The increase of
circulating myomiRs in the peripheral blood of dystrophic
patients correlates with the severity of the disease, suggesting
that myomiR quantification in blood of DMD patients might
represent a sensible diagnostic and prognostic marker [64,
94]. On the other hand our recent data, show a great increase
of FAPs derived myomiRs in muscle interstitium of mdx
mice after HDACi exposure suggesting an inverse correlation
between local and circulating myomiRs [19]. This suggests
that detection ofmuscular (local) versus circulatingmyomiRs
could provide a novel more accurate biomarker for diagnosis
of DMD progression and efficacy of therapeutic drugs [64].
MiR stability in extracellular environment seems to be
preserved by vesicles budding and intriguingly myomiRs
have been detected in vitro in exosomes released by mes-
enchymal cells to support myoblasts differentiation [101]. An
analogous mechanism is probably involved in vivo between
FAPs andMuSCs to promote muscle regeneration (Figure 2).
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It would be important to investigate if this functional cross-
talk mediated by exosome is somehow affected in muscle
disorders. Furthermore these data strongly encourage the
possibility to re-engineer naturally derived exosomes for
DMD epigenetic therapy.
6. Conclusions
In the last years, great advances have been made in the
comprehension of the epigenetic mechanisms regulating, via
chromatin organization, different transcriptional programs.
The functional characterization of the variety of epigenetic
regulations in healthy and disease states has the prospect to
identify novel targets for epigenetic-based therapies.
HDACi represent the first generation of epigenetic drugs.
Their clinical efficacy is currently being tested in a phase
I/II clinical trial on children affected by DMD. The pro-
regenerative effects of HDACi are mediated by FAPs, a pop-
ulation of muscle-resident stem cells. However, dystrophic
muscles at late stages of the disease are resistant to HDACi-
induced beneficial effects. This unresponsiveness might be
due to a decreased chromatin plasticity of FAPs caused by
epigenetic silencing pathways.The identification of the epige-
netic players preventing HDACi responsiveness at advanced
stages of DMD will be crucial to devise new personalized
and selective strategies to re-establish HDACi sensitivity. In
this context, a comprehensive epigenetic mapping of the
chromatin landscape of key populations involved in muscle
regeneration is becoming urgent to identify in the near future
both therapeutic effectiveness and inclusion criteria of DMD
patients to epigenetic therapy.
Exosome-bound miRNAs are emerging as a crucial
mechanism to transfer epigenetic information between cells.
New evidence showing the therapeutic relevance of these
vesicles in both unmodified and modified forms make them
attractive therapeutic agents for further study. Moreover
detection of specific miRNAs secreted in muscle interstitium
and blood of dystrophic patients holds the promise to develop
new painless methodologies, less invasive than classic biopsy,
such as blood sampling or fine needle aspiration techniques,
to diagnose DMD.
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